Abstract
It has been well recognized that investigator-initiated academic clinical trials is an important component in developing practice-changing cancer treatment, for instances, FOLFIRINOX in metastatic and resectable pancreatic cancer and FLOT in locally advanced gastric cancer. Because of the difference in prevalent cancer types, pharmacogenomics, tumor biology and/or associated genetic alterations, and new drug approval/reimbursement, clinical practice pattern and subsequent patient outcomes between Eastern and Western populations, the role for such academic clinical intervention trials, including real-world data (RWD) collection registration trials, to investigate the safety and efficacy of repurposing or new agents for new indications evaluation is even more relevant in Asia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
